Skip to main content
SpringerLink
Log in

Mucinous Carcinoma of the Ovary

  • Chapter
  • First Online:
Ovarian Cancers

  • 1074 Accesses

Abstract

Mucinous ovarian carcinoma is a rare tumor, but deserves separate attention, as its clinical behavior is quite different from other types of ovarian carcinoma. This has implications for both surgical therapy as well as adjuvant treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hess V, A’Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040–4.

    Article  CAS  PubMed  Google Scholar 

  2. Frumovitz M, Schmeler KM, Malpica A, et al. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491–6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331–4.

    Article  PubMed  Google Scholar 

  4. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985–93.

    Article  PubMed  Google Scholar 

  5. Mondal SK, Banyopadhyay R, Nag DR, et al. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital in eastern India. J Cancer Res Ther. 2011;4:433–7.

    Article  Google Scholar 

  6. Koonings PP. Relative frequencies of primary ovarian neoplasms: a 10-year review. Obstet Gynecol. 1989;74:921–6.

    CAS  PubMed  Google Scholar 

  7. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–41.

    Article  PubMed  Google Scholar 

  8. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.

    Article  CAS  PubMed  Google Scholar 

  9. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophos-phamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92:699–708.

    Article  CAS  PubMed  Google Scholar 

  10. Muggia FM, Braly PS, Brady MF, et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000;18:106–15.

    CAS  PubMed  Google Scholar 

  11. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419–25.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071–80.

    Article  PubMed  Google Scholar 

  13. Collaborative Group on Epidemiological Studies of Ovarian C; Beral V, Gaitskell K, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946–56.

    Google Scholar 

  14. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.

    Article  PubMed  Google Scholar 

  15. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: are we ready for a nomenclature change? Int J Gynecol Pathol. 2010;29:108–12.

    Article  PubMed  Google Scholar 

  16. Lee KR, Scully RE. Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with ‘pseudomyxoma peritonei’. Am J Surg Pathol. 2000;24:1447–64.

    Article  CAS  PubMed  Google Scholar 

  17. Rodriguez IM, Prat J. Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139–52.

    Article  PubMed  Google Scholar 

  18. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281–92.

    Article  PubMed  Google Scholar 

  19. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90:378–81.

    Article  CAS  PubMed  Google Scholar 

  20. Mok SC, Bell DA, Knapp RC, et al. Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res. 1993;53:1489–92.

    CAS  PubMed  Google Scholar 

  21. Mackenzie R, Kommoss S, Winterhoff BJ, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15:415. doi:10.1186/s12885-015-1421-8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Schuijer M, Berns EM. TP53 and ovarian cancer. Hum Mutat. 2003;21:285–91.

    Article  CAS  PubMed  Google Scholar 

  23. Marchini S, Mariani P, Chiorino G, et al. Analysis of gene expression in early-stage ovarian cancer. Clin Cancer Res. 2008;14:7850–60.

    Article  CAS  PubMed  Google Scholar 

  24. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. A distinct molecular profile associated with mucinous epithelial ovarian cancer. Br J Cancer. 2006;94:904–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Evans DG, Young K, Bulman M, et al. Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet. 2008;73:338–45.

    Article  CAS  PubMed  Google Scholar 

  27. Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229:111–20.

    Article  CAS  PubMed  Google Scholar 

  28. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006;30:1130–9.

    Article  PubMed  Google Scholar 

  30. Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and appendiceal origin from primary ovarian tumors of mucinous or endometrioid type. Am J Surg Pathol. 2016;40:419–32.

    Article  PubMed  Google Scholar 

  31. Cao D, Ji H, Ronnett BM. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary. Int J Gynecol Pathol. 2005;24:67–72.

    Article  PubMed  Google Scholar 

  32. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36:8–37.

    Article  CAS  PubMed  Google Scholar 

  33. Sarrio D, Moreno-Bueno G, Sanchez-Estevez C, et al. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37:1042–9.

    Article  CAS  PubMed  Google Scholar 

  34. Brun JL, Cortez A, Commo F, Uzan S, Rouzier R, Darai E. Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol. 2008;33:1239–46.

    CAS  PubMed  Google Scholar 

  35. Matsuo K, Masato M, Nishimura M, et al. Targeting Src in mucinous ovarian carcinoma. Clin Cancer Res. 2011;17:5367–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Riopel MA, Ronnett BM, Kurman RJ. Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas. Am J Surg Pathol. 1999;23:617–35.

    Article  CAS  PubMed  Google Scholar 

  37. Tait DL, Miller DS. Multicystic ovarian tumor weighing 156 lbs: the second largest tumor in Texas. Tex Med. 1997;93:89.

    CAS  PubMed  Google Scholar 

  38. Seidman JD, Horkayne-Szakaly I, Haiba M, et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23:41–4.

    Article  PubMed  Google Scholar 

  39. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269–73.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Kelly PJ, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63:169–73.

    Article  CAS  PubMed  Google Scholar 

  41. Nolen B, Marrangoni A, Velikokhatnaya L, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecol Oncol. 2009;112:47–54.

    Article  CAS  PubMed  Google Scholar 

  42. NCCN guidelines – ovarian cancer. Version 2.2013. Accessed on 20 Jan 2016.

    Google Scholar 

  43. Schilder JM, Thompson AM, DePriest PD, et al. Outcome of reproductive age women with stage IA or IC invasive epithelial ovarian cancer treated with fertility-sparing therapy. Gynecol Oncol. 2002;87:1–7.

    Article  PubMed  Google Scholar 

  44. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer. 2009;115:4118–26.

    Article  PubMed  Google Scholar 

  45. Lin JE, Seo S, Kushner DM, Rose SL. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013;208:46e41–4.

    Article  Google Scholar 

  46. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.

    Article  PubMed  Google Scholar 

  47. Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumours? Gynecol Oncol. 2006;103:878–82.

    Article  PubMed  Google Scholar 

  48. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J Clin Pathol. 2012;65:580–4.

    Article  CAS  PubMed  Google Scholar 

  49. Leys CM, Gasior AC, Hornberger LH, St. Peter SD. Laparoscopic resection of massive ovarian mucinous cystadenoma. J Laparoendosc Adv Surg Tech. 2012;22:307–10.

    Article  Google Scholar 

  50. Eltabbakh GH, Charbonneau AM, Eltabbakh NG. Laparoscopic surgery for large benign ovarian cysts. Gynecol Oncol. 2008;108:72–6.

    Article  PubMed  Google Scholar 

  51. Ledermann JA, Luvero D, Shafer A, O’Connor D, Mangili G, Friedlander M, Pfisterer J, Mirza MR, Kim JW, Alexandre J, Oza A, Brown J. Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma. Int J Gynecol Cancer. 2014;24(9 Suppl 3):S14–9.

    Article  PubMed  Google Scholar 

  52. Park JY, Heo EJ, Lee JW, Lee YY, Kim TJ, Kim BG, Bae DS. Outcomes of laparoscopic fertility-sparing surgery in clinically early-stage epithelial ovarian cancer. J Gynecol Oncol. 2016;27(2):e20.

    Article  PubMed  Google Scholar 

  53. Lee JY, Kim TH, Kim HS, Kim MA, Kim JW, Parek NH, Song YS. Safety of fertility-soaring surgery in primary mucinous carcinoma. Cancer Res Treat. 2015;47(2):290–7.

    Article  PubMed  Google Scholar 

  54. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early- stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105–12.

    Article  PubMed  Google Scholar 

  55. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436–41.

    Article  PubMed  Google Scholar 

  56. Simons M, Ezendam N, Bulten J, Nagtegall I, Massuger L. Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study. Int J Gynecol Cancer. 2015;25(7):1208–15.

    Article  PubMed  Google Scholar 

  57. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945–52.

    Article  PubMed  Google Scholar 

  58. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21:2377–81.

    Article  CAS  PubMed  Google Scholar 

  59. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2007;25:3621–7.

    Article  PubMed  Google Scholar 

  60. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176–82.

    Article  CAS  PubMed  Google Scholar 

  62. Ji J, Forsti A, Sundquist J, Lenner P, Hemminki K. Survival in ovarian cancer patients by histology and family history. Acta Oncol. 2008;47:1133–9.

    Article  PubMed  Google Scholar 

  63. Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci. 2009;100:546–51.

    Article  CAS  PubMed  Google Scholar 

  64. Shimizu Y, Umezawa S, Hasumi K. A phase II study of combined CPT-11 and mitomycin-C in platinum refractory clear cell and mucinous ovarian carcinoma. Ann Acad Med Singapore. 1998;27:650–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gynecologic Oncology and Reproductive Sciences, The University of Texas M.D. Anderson Cancer Center, 1155 Herman Pressler Blvd., Unit 1362, 301439, Houston, TX, 77030, USA

    Jubilee Brown MD & Michael Frumovitz MD

Authors
  1. Jubilee Brown MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Frumovitz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jubilee Brown MD .

Editor information

Editors and Affiliations

  1. AP-HP, Hôtel-Dieu, Paris, France

    Eric Pujade-Lauraine

  2. Centre Léon Bérard, Université Claude Bernard, Lyon, France

    Isabelle Ray-Coquard

  3. Chirurgie cancérologique, HEGP, Paris, France

    Fabrice Lécuru

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Brown, J., Frumovitz, M. (2017). Mucinous Carcinoma of the Ovary. In: Pujade-Lauraine, E., Ray-Coquard, I., Lécuru, F. (eds) Ovarian Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-32110-3_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32110-3_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32108-0

  • Online ISBN: 978-3-319-32110-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation